

Brilinta (Ticagrelor) is an antiplatelet medication for heart attack and stroke prevention. Learn about uses, dosage, cost, and more.
Brilinta (Ticagrelor) is a prescription antiplatelet medication used to reduce the risk of heart attack, stroke, and cardiovascular death in people with acute coronary syndrome or a history of heart attack.
Brilinta is the brand name for Ticagrelor, a medication in a class called P2Y12 platelet inhibitors. It's made by AstraZeneca and was first approved by the FDA for use in the United States.
Unlike older antiplatelet drugs like Clopidogrel (Plavix), Brilinta is not a prodrug — it doesn't need to be converted by your liver to work. This means it works the same way in everyone, regardless of genetics. Some patients are "poor metabolizers" of Clopidogrel due to variations in the CYP2C19 gene, which can make Clopidogrel less effective. Brilinta doesn't have this problem.
Brilinta is also reversible, meaning platelet function recovers faster after you stop taking it compared to Clopidogrel or Prasugrel (Effient), which bind permanently to platelets. For a detailed explanation, see our mechanism of action guide.
Brilinta is not a controlled substance and comes in two strengths: 60 mg and 90 mg oral tablets.
Brilinta is FDA-approved for three main indications:
This is the most common reason Brilinta is prescribed. ACS includes heart attacks (myocardial infarction) and unstable angina. After a cardiac event, your blood is more likely to form clots that could cause another heart attack or stroke. Brilinta, taken with low-dose aspirin, helps prevent those clots from forming.
For patients who have already had a heart attack, long-term Brilinta therapy (at the lower 60 mg dose) helps reduce the risk of future cardiovascular events. This is sometimes called secondary prevention.
Brilinta is also approved to reduce the risk of stroke and death in patients who've had an acute ischemic stroke or a high-risk transient ischemic attack (TIA, sometimes called a "mini-stroke").
Brilinta is an oral tablet taken twice daily. Here's how dosing typically works:
Important details about taking Brilinta:
Brilinta is not appropriate for everyone. You should not take Brilinta if you have:
Additionally, Brilinta should not be taken with:
For a complete list, see our Brilinta drug interactions guide.
If you're planning to have surgery — especially coronary artery bypass grafting (CABG) — tell your surgeon you're on Brilinta. It should be stopped at least 5 days before surgery when possible.
Cost is one of the biggest concerns for Brilinta patients. Here's what you can expect to pay:
For a complete breakdown of savings options, read our Brilinta savings guide.
The most common side effects of Brilinta include minor bleeding, shortness of breath (about 14% of patients), dizziness, nausea, diarrhea, and headache. The most serious risk is severe bleeding, which is covered by a boxed warning. For a detailed breakdown, see our Brilinta side effects guide.
Brilinta is an important medication for preventing heart attacks, strokes, and cardiovascular death. It works differently from older antiplatelet drugs — it doesn't depend on your genetics to be effective, and it wears off faster if you need surgery. It also costs more, though generic Ticagrelor has made it much more accessible in 2026.
If you've been prescribed Brilinta, take it exactly as directed, keep your aspirin dose at 100 mg or below, and never stop without talking to your doctor. If you're having trouble finding it or affording it, Medfinder can help you find pharmacies with stock and the best prices near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.